Welcome to our dedicated page for Collplant Biotechnologies news (Ticker: CLGN), a resource for investors and traders seeking the latest updates and insights on Collplant Biotechnologies stock.
CollPlant Biotechnologies (NASDAQ: CLGN) operates at the intersection of plant biotechnology and regenerative medicine, creating news flow that spans bioprinting research breakthroughs, clinical development milestones, and commercial partnership announcements. As a specialty biotechnology company producing recombinant human collagen from genetically engineered plants, CollPlant generates coverage distinct from traditional pharmaceutical or medical device companies.
News coverage for CollPlant typically includes research collaboration announcements with academic institutions and medical centers developing 3D bioprinting applications. The company's partnerships with organizations such as Mayo Clinic and Technion-Israel Institute of Technology produce updates on bioprinting advancements and preclinical study results. These announcements provide insight into the trajectory of tissue engineering applications using the company's rhCollagen technology.
Commercial developments form another significant news category, including distribution agreement expansions for the VergenixSTR product line across European and Asian markets. Patent grants and regulatory approvals for collagen-based formulations mark intellectual property milestones that affect the company's competitive position in the biomaterials sector.
As a dual-listed company on NASDAQ and the Tel Aviv Stock Exchange, CollPlant releases quarterly financial results and corporate updates that detail research progress, commercial traction, and capital position. These announcements help track the company's progress toward broader commercialization of its plant-derived collagen platform.
Bookmark this page to follow CollPlant's bioprinting research developments, tissue repair product expansions, and partnership announcements as the company advances its regenerative medicine technology.
CollPlant Biotechnologies (Nasdaq: CLGN) recently shared a CEO letter detailing significant advancements in 2021. Key collaborations include partnerships with Allergan for dermal fillers and 3D Systems for breast reconstruction matrices. The company's revenues skyrocketed to $15.3 million, supported by a $14 million payment from AbbVie. Operational costs were managed, with R&D expenses at $5.4 million. CollPlant is enhancing its production capabilities and expanding its IP portfolio. The firm aims to lead in regenerative medicine and plans to launch more innovative products in the near future.
CollPlant announced the publication of an article in the Plastic and Reconstructive Surgery journal showcasing its photocurable dermal filler. The filler demonstrated enhanced lifting effects and improved tissue regeneration in preclinical models compared to standard options. Composed of recombinant human collagen, the filler aims to provide efficient contour corrections. The company continues to forge partnerships for product development, including collaborations with Allergan and 3D Systems for broader applications in regenerative medicine.
CollPlant Biotechnologies (NASDAQ: CLGN) reported its third-quarter financial results for 2021, revealing GAAP revenue of $140,000, down from $4.1 million in Q3 2020. The company recorded a net loss of $3.1 million, or $0.29 per share. Operating expenses increased to $3.1 million from $2.0 million year-over-year. However, for the nine-month period ending September 30, 2021, revenue surged 173% to $15.3 million, bolstered by a $14 million upfront payment from AbbVie. The recent launch of Collink.3D, a novel bioink for 3D bioprinting, positions CollPlant within a potential multi-billion dollar market.
CollPlant Biotechnologies (Nasdaq: CLGN) has launched Collink.3D, a recombinant human collagen-based BioInk solution for 3D bioprinting of tissues and organs. This product is designed to improve the bio-functionality and safety of bioprinted constructs, potentially transforming drug discovery and tissue testing. Collink.3D is fully human-derived, providing a scalable method to produce transplantable tissues. The company aims to establish partnerships with biopharma and academia to enhance product development. The introduction of this BioInk positions CollPlant in a lucrative market with extensive future applications.
CollPlant Biotechnologies (Nasdaq: CLGN) announced that Deputy CEO & CFO Eran Rotem will present at the Dawson James 6th Annual Small Cap Growth Conference on October 21, 2021, from 12:15-12:35 PM ET in Jupiter, Florida. The company specializes in regenerative medicine and 3D bioprinting technologies, focusing on tissue regeneration and organ manufacturing. Recently, CollPlant entered a global agreement with Allergan for dermal fillers and a co-development agreement with 3D Systems for a breast reconstruction product.
CollPlant Biotechnologies (Nasdaq: CLGN) announced that its recombinant human collagen (rhCollagen)-based bioink was successfully utilized by researchers at Israel's Technion Institute for creating a 3D bioprinted tissue with a vascular network. This innovation has the potential for transplantation without rejection. CEO Yehiel Tal emphasized the significant implications of this study for regenerative medicine. The research demonstrated that the implanted tissue supported cell survival and functionality post-transplantation. This milestone could lead to advances in lab-grown tissues for various medical applications.
CollPlant Biotechnologies (NASDAQ: CLGN) will present at the virtual Fall Harvest – Best Ideas from the Buy-Side conference from October 5-8, 2021. CEO Yehiel Tal will speak on October 5 at 8:30 AM ET. The presentation will be webcast live and available for replay. CollPlant specializes in regenerative medicine and has recently collaborated with Allergan for dermal fillers and with 3D Systems for bioprinted tissue matrices for breast reconstruction. The company aims to innovate in medical aesthetics and tissue regeneration.
CollPlant (NASDAQ: CLGN) announced CEO Yehiel Tal's presentation at The International Nanotechnology Conference on October 6, 2021. Tal will discuss the company's rhCollagen technology platform, highlighting its growth strategy and product pipeline, which includes dermal fillers, BioInks, and 3D bioprinted breast implants. The event gathers top experts to explore innovations in nanotechnology. Recently, CollPlant entered significant agreements with Allergan and 3D Systems for product development, enhancing its market presence in regenerative medicine.
CollPlant (NASDAQ: CLGN) announced that its CEO, Yehiel Tal, has been elected to the Board of Directors of the International Society for Biofabrication (ISBF) for a three-year term starting January 1, 2022. This recognition is due to his expertise in the 3D bioprinting industry. Tal expressed his honor in contributing to advancements in biofabrication, which plays a critical role in tissue engineering and regenerative therapies. The ISBF focuses on promoting innovations in biofabrication for the betterment of humanity.
CollPlant (NASDAQ: CLGN), a leader in regenerative and aesthetic medicine, will present at the virtual H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. CEO Yehiel Tal will overview the company's advancements, available on-demand from 7 a.m. EST on September 13. CollPlant specializes in 3D bioprinting with its rhCollagen technology, recently forming partnerships with Allergan and 3D Systems for dermal fillers and breast reconstruction. For more details, visit CollPlant's website.
FAQ
What is the current stock price of Collplant Biotechnologies (CLGN)?
What is the market cap of Collplant Biotechnologies (CLGN)?
